A Study of Nivolumab In Combination With Cabozantinib in Patients With

Updated 04/26/2024

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
Carcinoma
Carcinoma, Renal Cell
Chromophobe Renal Cell Carcinoma
Collecting Duct Renal Cell Carcinoma
Fumarate Hydratase Deficient Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Succinate Dehydrogenase Deficient Renal Cell Carcinoma
Unclassified Renal Cell Carcinoma

Clinical Trial Details

NCT number	NCT03635892
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 13, 2018
Completion date	August 2024

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04623502` - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy	N/A
	Recruiting	`NCT05043090` - Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC	Phase 3
	Completed	`NCT02489695` - Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma	Phase 2
	Terminated	`NCT00098618` - Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer	Phase 2
	Withdrawn	`NCT04603365` - Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer	Phase 2
	Recruiting	`NCT05620134` - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Phase 1/Phase 2
	Recruiting	`NCT04413123` - Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC	Phase 2
	Completed	`NCT00126503` - Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	Phase 1/Phase 2
	Active, not recruiting	`NCT01767636` - Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer	Phase 2
	Active, not recruiting	`NCT03541902` - Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma	Phase 2
	Recruiting	`NCT03866382` - Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	Phase 2
	Terminated	`NCT02837991` - A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma	Phase 1
	Completed	`NCT00335556` - Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors	Phase 2
	Recruiting	`NCT04981509` - Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer	Phase 2
	Recruiting	`NCT04071223` - Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study	Phase 2
	Recruiting	`NCT00898365` - Study of Kidney Tumors in Younger Patients
	Recruiting	`NCT06339138` - Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
	Not yet recruiting	`NCT06146777` - Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy	Phase 3